vTv Therapeutics Inc. filings document the regulatory record of a Nasdaq-listed, late-stage biopharmaceutical company developing oral small-molecule candidates for diabetes and other chronic diseases. Form 8-K reports cover financial results, Regulation FD investor presentations, material agreements, and clinical or regulatory disclosures tied to cadisegliatin and other pipeline assets.
The company’s filings also disclose licensing arrangements involving vTv Therapeutics LLC and HPP737, capital-structure and security-related matters, and governance information in proxy materials. Definitive proxy statements describe board matters, executive compensation, equity awards, shareholder voting items, and related corporate-governance disclosures.
vTv Therapeutics Inc. filed an 8-K describing an update to its existing at-the-market stock sales program. The company has filed a prospectus supplement with the SEC to increase the number of Class A common shares offered under this program to the full amount allowed by the ATM agreement.
To support these issuances, vTv is also filing a legal opinion from Dechert LLP on the validity of the Class A common stock issuable under the ATM program. This opinion is attached as Exhibit 5.1 and is being incorporated by reference into the company’s effective shelf registration statement on Form S-3.
vTv Therapeutics reported a sharp turnaround in the quarter ended March 31, 2026, driven by licensing revenue. Revenue reached $36.8 million, all from collaboration and license agreements, primarily a $20.0 million upfront payment and additional milestone and license revenue from Newsoara and G42.
Research and development expenses rose to $9.0 million from $2.8 million as the company advanced its lead Type 1 diabetes candidate cadisegliatin and other projects. General and administrative costs increased to $4.6 million. vTv generated net income of $24.1 million, compared with a $6.2 million loss a year earlier.
Cash and cash equivalents grew to $98.1 million from $88.9 million at year-end 2025, helped by the Newsoara payment and recognition of deferred G42 license consideration, giving the company more flexibility to fund ongoing Phase 3 and supporting trials for cadisegliatin and other pipeline work.
vTv Therapeutics Inc. reported a strong turnaround in its first quarter ended March 31, 2026, driven by a major licensing payment. Revenue was $36.8 million, compared with none a year earlier, and net income attributable to shareholders reached $24.1 million versus a prior net loss of $5.1 million.
The company ended the quarter with $98.1 million in cash and cash equivalents and expects this to fund operations through the anticipated topline data readout from its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. An amended license agreement with Newsoara Biopharma added a $20.0 million upfront payment and potential milestones while keeping strategic focus on cadisegliatin.
vTv Therapeutics Inc. is asking stockholders to vote at a virtual-only 2026 annual meeting on June 10, 2026. Investors will elect seven directors and vote on ratifying Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
The board is fixed at seven members and includes nominees designated under an Amended Investor Rights Agreement and a 2024 Securities Purchase Agreement, giving key investors specified board nomination rights and requiring supermajority board approval for major corporate actions for three years. The company describes its governance structure, committee composition and independence, director pay (cash retainers plus stock options), and detailed executive compensation for 2025, including employment terms and severance protections for the CEO and CFO. The proxy also outlines ownership of about 3.94 million shares on an as-converted basis, with large positions held by MacAndrews & Forbes and several institutional investors.
Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander filed an Amendment No. 1 to a Schedule 13G/A reporting shared beneficial ownership of Class A Common Stock.
The filing shows Integrated Core Strategies (US) LLC with shared voting and dispositive power of 198,748 shares5.0%), and Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each with shared voting and dispositive power of 225,073 shares5.7% each). The entities filed a Joint Filing Agreement dated April 15, 2026.
vTv Therapeutics Inc. Schedule 13G reports that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander together disclose shared voting and dispositive power over 198,237 shares of Class A Common Stock, representing 5.0% of the class as shown on the cover page dated 03/24/2026.
The filing states these shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers, and includes a Joint Filing Agreement dated 03/26/2026.
vTv Therapeutics Inc. furnished an updated investor presentation highlighting its diabetes-focused pipeline. The deck centers on cadisegliatin (TTP399), a hepatoselective glucokinase activator in Phase 3 CATT1 for type 1 diabetes, which has FDA Breakthrough Therapy Designation and aims to be the first oral adjunctive T1D therapy in the U.S. Phase 2 SimpliciT1 data showed a 0.36% HbA1c reduction versus insulin alone and about 50% fewer symptomatic hypoglycemic episodes, with no diabetic ketoacidosis and a generally similar adverse-event profile to placebo. An earlier T2D study showed a 0.9% HbA1c reduction versus metformin. The presentation states cash of $88.9 as of 12/31/2025 plus an additional $20 received on 2/2/2026, which the company says supports operations past the expected CATT1 topline readout. vTv also outlines partnered programs in psoriasis, cancer, and regional T2D markets, and internal assets including an oral GLP-1 agonist (TTP273) and Nrf2/Bach1 modulators targeting oxidative inflammation.
vTv Therapeutics Inc. reported fourth quarter and full year 2025 results and provided a clinical and corporate update. Cash and cash equivalents were $88.9 million as of December 31, 2025, up from $36.7 million a year earlier, mainly from prior private financing.
For 2025, research and development expenses rose to $17.9 million and general and administrative expenses to $14.9 million. Net loss attributable to vTv shareholders was $27.0 million, or $3.20 per basic share.
The company received a $20.0 million upfront payment in February 2026 from an amended global license with Newsoara for PDE4 inhibitor HPP737, with potential future milestones and royalties. vTv expects to complete enrollment in the CATT1 Phase 3 trial of cadisegliatin for type 1 diabetes in the third quarter of 2026 and states that its strengthened balance sheet funds operations well past the anticipated Phase 3 topline readout.
vTv Therapeutics Inc. files its annual report describing a late-stage biopharmaceutical business focused on orally administered therapies for metabolic and inflammatory diseases, led by cadisegliatin (TTP399) for type 1 diabetes.
Cadisegliatin has FDA Breakthrough Therapy designation and is in the Phase 3 CATT1 trial, which will randomize 150 patients to assess reductions in severe hypoglycemia and improvements in HbA1c. The program recently resumed after the FDA lifted a clinical hold in March 2025.
The company broadened its pipeline with candidates targeting GLP‑1, RAGE, PPAR‑δ and Nrf2/Bach1 pathways and expanded partnered programs, including global rights to PDE4 inhibitor HPP737 licensed to Newsoara. In 2025 it closed an $80 million private placement, plus a $20 million upfront payment from Newsoara, supporting development beyond topline CATT1 data. As of March 10, 2026, vTv had 3,938,654 Class A common shares outstanding.
vTv Therapeutics Inc. released an updated investor presentation outlining its diabetes-focused pipeline and financial position. The company highlights cadisegliatin, an oral glucokinase activator in Phase 3 development as a potential first oral adjunctive therapy for type 1 diabetes in the U.S., with topline CATT1 study data targeted for the second half of 2026.
The presentation cites prior Phase 2 data in T1D showing a 0.36% reduction in HbA1c versus insulin alone and a 50% reduction in symptomatic hypoglycemic episodes, with no diabetic ketoacidosis. Cadisegliatin has FDA Breakthrough Therapy Designation. vTv reports $98 million in cash as of September 30, 2025, plus an additional $20 million received on February 2, 2026, which it says provides runway well past the CATT1 topline readout.
The company also describes additional clinical and preclinical programs in immunology, inflammation, metabolism, oncology, obesity, and oxidative inflammation, along with regional partnerships that could generate royalties and shared economics. Management emphasizes its experienced leadership team and positions the broader portfolio as offering potential non-dilutive funding and future revenue streams.